This event, Part III in a three part series that will explore the value of health, will consider disruptions to the ever-evolving value, access & reimbursement landscape as new players enter the arena and others consolidate. What impact will mergers between payers and PBMs have on drug pricing, patient access, and the ability to track and analyze data? How are digital technologies changing the way we track patients and ensure access? What impact will one-time cures have on the system? What new financing methodologies are gaining traction and what else can we do to support their widespread adoption?  What new players are disrupting the value equation? We’ll attempt to answer those questions and more, with MassBio’s Bob Coughlin as the moderator.

We believe this issue is especially timely. We’re at an inflection point, with science that’s been tested for decades finally becoming a reality for patients and a payer system that has not caught up with this level of innovation. Myriad factors are combining to alter the status quo – with policymakers demanding action, and healthcare stakeholders agreeing that we must come up with real solutions. If we don’t come together and address the value equation as an industry and ensure patient access to all new therapies, government or other stakeholders will – and they will likely get it wrong.

Drinks and appetizers will be provided. If you’re not a MassBio member but are interested in attending, please email contact us at communications@massbio.org.